Carcinosarcoma of the ovary treated with platinum and taxane: The memorial Sloan-Kettering Cancer Center experience

Gynecologic Oncology

Volumn 105, Issue 3, 2007, Pages 657-661

  Leiser, Aliza L ^a   Chi, Dennis S ^a   Ishill, Nicole M ^a   Tew, William P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ovarian carcinosarcoma; Platinum; Taxane

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CENTER; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DATA EXTRACTION; DISEASE COURSE; HUMAN; MEDICAL RECORD; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PRIORITY JOURNAL; SARCOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 34248383614     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.01.037     Document Type: Article

References (27)

1. Bicher A., Levenback C., Silva E.G., Burke T.W., Morris M., and Gershenson D.M. Ovarian malignant mixed mullerian tumors treated with platinum-based chemotherapy. Obstet. Gynecol. 85 5 Pt 1 (1995) 735-739
2. McCluggae W.G. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?. J. Clin. Pathol. 55 5 (2002) 321-325
3. Brown E., Stewart M., Rye T., Al-Nafussi A., Williams A.R., Bradburn M., et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 100 (2004) 2148-2153
4. Masuda A., Takeda A., Fukami H., Yamada C., and Matsuyama M. Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary. Carcinomatous cells are changeable to sarcomatous cells. Cancer 60 11 (1987) 2696-2703
5. Kounelis S., Jones M.W., Papadaki H., Bakker A., Swalsky P., and Finkelstein S.D. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum. Pathol. 29 (1998) 82-87
6. Sood A.K., Sorosky J.I., Gelder M.S., Buller R.E., Anderson B., Wilkinson E.J., et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer 82 9 (1998) 1731-1737
7. Tate Thigpen J., Blessing J.A., DeGeest K., Look K.Y., Homesley H.D., and Gynecologic Oncology Group. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol. Oncol. 93 2 (2004) 336-339
8. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 1 (1996) 1-6
9. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000) 205-216
10. Rustin G.J., Nelstrop A.E., McClean P., et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14 5 (1996) 1545-1551
11. Barakat R.R., Almadrones L., Venkatraman E.S., Aghajanian C., Brown C., Shapiro F., et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol. Oncol. 69 1 (1998) 17-22
12. McCreath W.A., Eisenhauer E.L., Abu-Rustum N.R., Venkatraman E.S., Caceres A., Bier R., et al. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma. Gynecol. Oncol. 102 1 (2006) 8-14
13. Prendiville J., Murphy D., Renninson J., Buckley H., and Crowther D. Carcinosarcoma of the ovary treated over a 10-year period at the Christie Hospital. Int. J. Gynecol. Cancer 4 3 (1994) 200-205
14. Andersen W.A., Young D.E., Peters III W.A., Smith E.B., Bagley C.M., and Taylor Jr. P.T. Platinum-based combination chemotherapy for malignant mixed mesodermal tumors of the ovary. Gynecol. Oncol. 32 3 (1989) 319-322
15. Rutledge T.L., Gold M.A., McMeekin D.S., Huh W.K., Powell M.A., Lewin S.N., et al. Carcinosarcoma of the ovary-a case series. Gynecol. Oncol. 100 1 (2006) 128-132
16. Thigpen J.T., Blessing J.A., Olt G., Lentz S.S., and Bell J. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group Study. Gynecol. Oncol. 90 3 (2003) 581-586
17. Sutton G., Brunetto V.L., Kilgore L., Soper J.T., McGehee R., Olt G., et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol. Oncol. 79 2 (2000) 147-153
18. Sit A.S., Price F.V., Kelley J.L., Comerci J.T., Kunschner A.J., Kanbour-Shakir A., et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol. Oncol. 79 2 (2000) 196-200
19. Sutton G.P., Blessing J.A., Homesley H.D., and Malfetano J.H. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group Study. Gynecol. Oncol. 53 1 (1994) 24-26
20. Thompson L., Chang B., and Barsky S.H. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am. J. Surg. Pathol. 20 3 (1996) 277-285
21. Duska L.R., Garrett A., Eltabbakh G.H., Oliva E., Penson R., and Fuller A.F. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol. Oncol. 85 3 (2002) 459-463
22. Eltabbakh G.H., and Yadav R. Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy. Eur. J. Gynaecol. Oncol. 20 5-6 (1999) 355-356
23. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 21 17 (2003) 3194-3200
24. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 22 (2004) 1682-1691
25. Barakat R.R., Rubin S.C., Wong G., Saigo P.E., Markman M., and Hoskins W.J. Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet. Gynecol. 80 4 (1992) 660-664
26. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 103 3 (2006) 1083-1090
27. Mok J.E., Kim Y.M., Jung M.H., Kim K.R., Kim D.Y., Kim J.H., et al. Malignant mixed mullerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy. Int. J. Gynecol. Cancer 16 1 (2006) 101-105